Nicholas Navin, Ph.D.
Areas of Research
- Genomics Research
- Breast Cancer Research
- Genetics Research
Welcome to the Navin Laboratory at MD Anderson Cancer Center. We are a cancer genomics and computational biology research lab. Our laboratory has pioneered the development of single cell sequencing technologies. We apply these tools to study complex biological processes that occur in human cancers including transformation, clonal evolution, invasion, metastasis and chemoresistance evolution. These processes have previously been difficult to study with genomic technologies using bulk tissues.
The efforts of our laboratory are split evenly between experimental and computational biology. We develop new experimental methods to sequence single cells and isolate rare subpopulations and develop new analytical appraches to detect variants and apply statistical methods to these data sets.
Single-Cell Sequencing Pioneer Wins AAAS Wachtel Cancer Research Award
The first method for sequencing the genome of an individual cell - which has give scientists a new view into the inner workings of tumors - started as a side project during Nicholas Navin's graduate career.
Life in the Lab
A new study sheds light on how tumors evolve
We were recently featured in Cancer Frontline regarding our new study that used single-cell sequencing technology to provide previously unknown details about how and when CNAs impact tumor formation and growth.
ACS Research Scholar
Sabin Family Fellowship
President's Achievement Award
Faculty Scholar Award
AAAS Wachtel Prize for Young Scientists
Faculty Educator Award
Wilson Stone Award
T.C. Hsu Award for Young Investigators
Damon Runyon-Rachleff Innovation
Young Investigator Award
We are actively developing novel computational and statistical methods for analyzing large-scale single cell DNA and RNA sequencing datasets. Our primary focus is on breast cancer patients. At MD Anderson we are uniquely positioned to translate our single cell sequencing methods into the clinic, to improve early detection, non-invasive monitoring, diagnostics and guiding targeted therapy. These clinical applications are expected to have a major impact on reducing morbidity in cancer patients and improving their quality of life.